Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 16/20 | 0.49 |
| ▸ | KDM1A | O60341 | 1/20 | 0.49 |
| ▸ | CDK2 | P24941 | 5/20 | 0.48 |
| ▸ | KDR | P35968 | 4/20 | 0.48 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 2/20 | 0.47 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
| ▸ | ACACB | O00763 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29722778 | 1.00 | EGFR (0.49) | EGFRKDM1ACDK2KDRMAP4K4 | |
| SCHEMBL30068037 | 0.84 | ACACB (0.41) | EGFRKDM1ACDK2KDRMAP4K4 | |
| SCHEMBL25063680 | 0.84 | PIK3CA (0.45) | EGFRKDM1ACDK2KDRPDE4D | |
| SCHEMBL31509588 | 0.83 | MAP4K4 (0.51) | EGFRKDM1ACDK2KDRMAP4K4 | |
| SCHEMBL24827231 | 0.83 | ACHE (0.52) | KDM1APDE4D | |
| SCHEMBL23593426 | 0.82 | KDM1A (0.45) | EGFRKDM1ACDK2KDRPDE4D | |
| SCHEMBL15748899 | 0.82 | EGFR (0.49) | EGFRCDK2KDRJAK2AURKB | |
| SCHEMBL23593425 | 0.80 | KDM1A (0.43) | EGFRKDM1ACDK2KDRPDE4D | |
| SCHEMBL23578956 | 0.79 | KDM1A (0.45) | EGFRKDM1APDE4D | |
| SCHEMBL24970580 | 0.79 | KDM1A (0.42) | EGFRKDM1ACDK2KDRPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250289801-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2025-09-18 | — | — | US | disclosed |
| US-20250129047-A1 | ISOQUINOLINE DERIVATIVES AS MUTANT EGFR MODULATORS AND USES THEREOF | NEWAVE PHARMACEUTICAL INC (US) | 2025-04-24 | — | — | US | disclosed |
| US-12172983-B2 | EGFR inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2024-12-24 | — | — | US | disclosed |
| US-20240382599-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2024-11-21 | — | — | US | disclosed |
| US-20240115711-A1 | Novel Bifunctional Molecules For Targeted Protein Degradation | AMPHISTA THERAPEUTICS LIMITED (GB) | 2024-04-11 | — | — | US | disclosed |
| EP-4263511-A1 | NOVEL BIFUNCTIONAL MOLECULES FOR TARGETED PROTEIN DEGRADATION | Amphista Therapeutics Ltd (GB) | 2023-10-25 | — | — | EP | disclosed |
| CN-116897150-A | Novel bifunctional molecules for protein-targeted degradation | 安菲斯塔治疗有限公司 | 2023-10-17 | — | — | CN | disclosed |
| US-11718602-B2 | EGFR inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2023-08-08 | — | — | US | disclosed |
| US-11718602-B2 | EGFR inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2023-08-08 | — | — | US | disclosed |
| US-11718602-B2 | EGFR inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2023-08-08 | — | — | US | disclosed |
| US-20160257682-A1 | AZAINDAZOLE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | GENENTECH, INC. (US) | 2016-09-08 | — | — | US | disclosed |
| US-20160257682-A1 | AZAINDAZOLE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | GENENTECH, INC. (US) | 2016-09-08 | — | — | US | disclosed |
| EP-3052494-A1 | AZAINDAZOLE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | Genentech, Inc. (US) | 2016-08-10 | — | — | EP | disclosed |
| US-20160016948-A1 | AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | GENENTECH, INC. (US) | 2016-01-21 | — | — | US | disclosed |
| US-20160016948-A1 | AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | GENENTECH, INC. (US) | 2016-01-21 | — | — | US | disclosed |
| US-20160016948-A1 | AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | GENENTECH, INC. (US) | 2016-01-21 | — | — | US | disclosed |
| EP-2922851-A1 | AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | Genentech, Inc. (US) | 2015-09-30 | — | — | EP | disclosed |
| WO-2014210354-A1 | AZAINDAZOLE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | GENENTECH, INC. (US) | 2014-12-31 | — | — | WO | disclosed |
| WO-2014210354-A1 | AZAINDAZOLE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | GENENTECH, INC. (US) | 2014-12-31 | — | — | WO | disclosed |
| WO-2014081718-A1 | AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | GENENTECH, INC. (US) | 2014-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240382599-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | TBK1, EGFR, CBL | EGFR 2/4885KDM1A 1653/4885CDK2 2122/4885 |
| US-20250129047-A1 | ISOQUINOLINE DERIVATIVES AS MUTANT EGFR MODULATORS AND USES THEREOF | EGFR, ERBB2, ERBB4 | EGFR 1/4885KDM1A 3422/4885CDK2 45/4885 |
| US-11718602-B2 | EGFR inhibitors | EGFR, ERBB2, ERBB3 | EGFR 1/4885KDM1A 3493/4885CDK2 691/4885 |
| US-12172983-B2 | EGFR inhibitors | EGFR, ERBB2, ERBB3 | EGFR 1/4885KDM1A 3493/4885CDK2 691/4885 |
| US-20160016948-A1 | AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | EGFR, ERBB2, ERBB3 | EGFR 1/4885KDM1A 3732/4885CDK2 32/4885 |
| US-20240115711-A1 | Novel Bifunctional Molecules For Targeted Protein Degradation | PSMG3, MYCBP2, PSME2 | EGFR 2452/4885KDM1A 4105/4885CDK2 2059/4885 |
| US-20250289801-A1 | EGFR INHIBITORS | EGFR, ERBB2, ERBB3 | EGFR 1/4885KDM1A 3493/4885CDK2 691/4885 |
| US-20160257682-A1 | AZAINDAZOLE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | EGFR, ERBB2, ERBB3 | EGFR 1/4885KDM1A 1837/4885CDK2 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.